文献速递复苏、休克与脓毒症呼吸衰竭与机械通气重症综合管理与镇静镇痛

标准剂量预防、高剂量预防与治疗剂量抗凝对低氧性COVID-19肺炎患者的影响:ANTICOVID随机临床试验

Effects of Standard-Dose Prophylactic, High-Dose Prophylactic, and Therapeutic Anticoagulation in Patients With Hypoxemic COVID-19 Pneumonia: The ANTICOVID Randomized Clinical Trial.
PubMed 文献 · JAMA Intern Med · 2023-01-01
一句话结论在低氧性COVID-19肺炎患者中,与标准剂量预防抗凝相比,高剂量预防或治疗剂量抗凝未改善28天全因死亡或临床改善时间这一主要分层终点,但高剂量预防抗凝通过降低新发血栓风险显著改善了净临床结局。

ANTICOVID是在法国23个中心开展的开放标签随机临床试验,2021年4月14日至12月13日纳入339例需补充氧气且胸部CT血管造影无初始血栓的低氧性COVID-19肺炎患者,随机接受标准剂量预防抗凝(SD-PA,114例)、高剂量预防抗凝(HD-PA,110例)或治疗剂量抗凝(TA,110例)14天,随机时90%患者在ICU。主要终点为28天全因死亡后接临床改善时间的分层复合终点,三组两两比较均无显著差异(HD-PA vs SD-PA P=0.48,TA vs SD-PA P=0.82,TA vs HD-PA P=0.37)。净临床结局(血栓、大出血和全因死亡复合)在SD-PA组为29.8%,HD-PA组16.4%,TA组20.0%;HD-PA和TA较SD-PA均显著降低血栓(绝对差均为-14.7,95%CI -6.2至-23.2),HD-PA较SD-PA显著改善净临床结局(绝对差-13.5,95%CI -2.6至-24.3)。

要点

  • 在需补充氧气的低氧性COVID-19肺炎患者中,HD-PA与SD-PA的主要分层终点(28天全因死亡后接临床改善时间)无显著差异(有利结局概率47.3% vs 52.7%,P=0.48)。
  • TA与SD-PA的主要分层终点无显著差异(有利结局概率50.9% vs 49.1%,P=0.82),TA与HD-PA亦无显著差异(53.5% vs 46.5%,P=0.37)。
  • HD-PA和TA较SD-PA显著降低血栓发生率(绝对差均为-14.7,95%CI -6.2至-23.2)。
  • HD-PA较SD-PA显著改善净临床结局(绝对差-13.5,95%CI -2.6至-24.3),净临床结局发生率SD-PA组29.8%、HD-PA组16.4%、TA组20.0%。
  • SD-PA组血栓20.2%、出血2.6%、死亡14.0%;HD-PA组血栓5.5%、出血3.6%、死亡11.8%;TA组血栓5.5%、出血3.6%、死亡12.7%。

适用人群与场景

  • 需补充氧气的低氧性COVID-19肺炎成人患者,且胸部CT血管造影无初始血栓。
  • 随机时90%的患者在ICU。
  • 法国23个健康中心,2021年4月14日至12月13日纳入。

处置流程与药物剂量

  • 患者按1:1:1随机接受标准剂量预防抗凝(SD-PA)、高剂量预防抗凝(HD-PA)或治疗剂量抗凝(TA),使用低分子量肝素或普通肝素,疗程14天。

研究设计与关键结果

  • ANTICOVID为开放标签随机临床试验,纳入339例患者,334例纳入主要分析(SD-PA组114例、HD-PA组110例、TA组110例),平均(SD)年龄58.3(13.0)岁,男性226例(67.7%)、女性108例(32.3%)。
  • 主要分层终点(28天全因死亡后接临床改善时间):HD-PA与SD-PA有利结局概率47.3%(95%CI 39.9%至54.8%)vs 52.7%(95%CI 45.2%至60.1%),P=0.48;TA与SD-PA为50.9%(95%CI 43.4%至58.3%)vs 49.1%(95%CI 41.7%至56.6%),P=0.82;TA与HD-PA为53.5%(95%CI 45.8%至60.9%)vs 46.5%(95%CI 39.1%至54.2%),P=0.37。
  • 净临床结局(血栓、大出血和全因死亡复合)发生率:SD-PA组29.8%(血栓20.2%、出血2.6%、死亡14.0%),HD-PA组16.4%(血栓5.5%、出血3.6%、死亡11.8%),TA组20.0%(血栓5.5%、出血3.6%、死亡12.7%)。
  • HD-PA和TA较SD-PA显著降低血栓(绝对差均为-14.7,95%CI -6.2至-23.2)。
  • HD-PA较SD-PA显著改善净临床结局(绝对差-13.5,95%CI -2.6至-24.3)。

证据类型、等级与局限

  • 证据类型:随机对照试验(开放标签)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在需补充氧气的低氧性COVID-19肺炎患者中,与SD-PA相比,HD-PA或TA未改善28天全因死亡或临床改善时间这一主要分层终点;但HD-PA通过降低新发血栓风险显著改善了净临床结局。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Given the high risk of thrombosis and anticoagulation-related bleeding in patients with hypoxemic COVID-19 pneumonia, identifying the lowest effective dose of anticoagulation therapy for these patients is imperative.

OBJECTIVES: To determine whether therapeutic anticoagulation (TA) or high-dose prophylactic anticoagulation (HD-PA) decreases mortality and/or disease duration compared with standard-dose prophylactic anticoagulation (SD-PA), and whether TA outperforms HD-PA; and to compare the net clinical outcomes among the 3 strategies.

DESIGN, SETTINGS, AND PARTICIPANTS: The ANTICOVID randomized clinical open-label trial included patients with hypoxemic COVID-19 pneumonia requiring supplemental oxygen and having no initial thrombosis on chest computer tomography with pulmonary angiogram at 23 health centers in France from April 14 to December 13, 2021. Of 339 patients randomized, 334 were included in the primary analysis-114 patients in the SD-PA group, 110 in the HD-PA, and 110 in the TA. At randomization, 90% of the patients were in the intensive care unit. Data analyses were performed from April 13, 2022, to January 3, 2023.

INTERVENTIONS: Patients were randomly assigned (1:1:1) to receive either SD-PA, HD-PA, or TA with low-molecular-weight or unfractionated heparin for 14 days.

MAIN OUTCOMES AND MEASURES: A hierarchical criterion of all-cause mortality followed by time to clinical improvement at day 28. Main secondary outcome was net clinical outcome at day 28 (composite of thrombosis, major bleeding, and all-cause death).

RESULTS: Among the study population of 334 individuals (mean [SD] age, 58.3 [13.0] years; 226 [67.7%] men and 108 [32.3%] women), use of HD-PA and SD-PA had similar probabilities of favorable outcome (47.3% [95% CI, 39.9% to 54.8%] vs 52.7% [95% CI, 45.2% to 60.1%]; P = .48), as did TA compared with SD-PA (50.9% [95% CI, 43.4% to 58.3%] vs 49.1% [95% CI, 41.7% to 56.6%]; P = .82) and TA compared with HD-PA (53.5% [95% CI 45.8% to 60.9%] vs 46.5% [95% CI, 39.1% to 54.2%]; P = .37). Net clinical outcome was met in 29.8% of patients receiving SD-PA (20.2% thrombosis, 2.6% bleeding, 14.0% death), 16.4% receiving HD-PA (5.5% thrombosis, 3.6% bleeding, 11.8% death), and 20.0% receiving TA (5.5% thrombosis, 3.6% bleeding, 12.7% death). Moreover, HD-PA and TA use significantly reduced thrombosis compared with SD-PA (absolute difference, -14.7 [95% CI -6.2 to -23.2] and -14.7 [95% CI -6.2 to -23.2], respectively). Use of HD-PA significantly reduced net clinical outcome compared with SD-PA (absolute difference, -13.5; 95% CI -2.6 to -24.3).

CONCLUSIONS AND RELEVANCE: This randomized clinical trial found that compared with SD-PA, neither HD-PA nor TA use improved the primary hierarchical outcome of all-cause mortality or time to clinical improvement in patients with hypoxemic COVID-19 pneumonia; however, HD-PA resulted in significantly better net clinical outcome by decreasing the risk of de novo thrombosis.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04808882.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Labbé V, Contou D, Heming N, et al. Effects of Standard-Dose Prophylactic, High-Dose Prophylactic, and Therapeutic Anticoagulation in Patients With Hypoxemic COVID-19 Pneumonia: The ANTICOVID Randomized Clinical Trial. JAMA Intern Med. 2023. PMID: 36946232. doi:10.1001/jamainternmed.2023.0456

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。